Humanigen Inc (HGENQ)

[Fezziwig2008]

HGEN Ready for FDA EUA ramping up manufacturing ability:

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)--Catalent and Humanigen, Inc. (HGEN) (“Humanigen”) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

“If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics’ deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.”